Short Wave COVID And Aduhelm On The Agenda At Denver Alzheimer's Meeting
Aug 4, 2021
Join Jon Hamilton, NPR science correspondent, as he unpacks the latest findings from the Alzheimer's Association International Conference in Denver. He discusses the controversial FDA approval of Aduhelm, a new drug for Alzheimer's, while addressing its safety concerns. Hamilton also delves into the intriguing evidence linking COVID-19 to cognitive decline and increased Alzheimer's risk, particularly in older adults. His insights shed light on the ethical implications and the need for further research, especially concerning underrepresented populations.
AI Snips
Chapters
Transcript
Episode notes
COVID's Impact on a Nurse
- Cassandra Hernandez, a 38-year-old nurse, experienced severe cognitive impairment after contracting COVID-19.
- She had difficulty with memory, thinking, and even maintaining conversations due to fatigue.
COVID and Brain Damage
- Research suggests a link between COVID-19 and lasting brain damage, especially in those with loss of taste/smell.
- Older adults may experience forgetfulness and language issues resembling early Alzheimer's.
COVID and Alzheimer's Risk
- It is uncertain if COVID-19 increases Alzheimer's risk, requiring long-term studies.
- Millions already face persistent cognitive problems post-COVID, making further research crucial.